Biogen Idec seeks $1b payoff from solving Lou Gehrig puzzle
Biogen Idec Inc. chief executive George Scangos was skeptical when he learned company researchers were pursuing a new treatment for Lou Gehrig’s disease. No one knows the cause of the illness that killed the famous baseball player more than 70 years ago, and no medicine for it has been shown to slow its advance for long. Scangos changed his mind. A company drug candidate that may slow disease progression is now in the final stages of clinical trials. Biogen Idec is headquartered in Weston.